Biologic medicines have changed the world of healthcare by positively transforming the treatment of many life-limiting diseases. This success story is one Boehringer Ingelheim has helped to write. As an industry leader in the production of biologics, we have to date manufactured more than 25 biologic medicines for global markets.
Based on the biotechnological advancements, the development of biosimilars, which are clinically equivalent alternatives to the approved reference biologic, has become a reality. To the healthcare community, the potential benefits are compelling, with the opportunity to expand overall treatment options while striving to make healthcare systems more sustainable.
At Boehringer Ingelheim, we are committed to improving the lives of patients by exploring innovative ways for biosimilars to contribute to the quality and economic sustainability of healthcare. We know that value extends beyond the product itself, so we proactively seek strategic partnerships and welcome innovative collaborations to improve the overall experience that patients, providers, and payers have with biologics.